[Prevention and therapy of thromboembolism: rivaroxaban - better outcome - risk profile as standard therapy].
D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy; D002986:Clinical Trials as Topic; D057915:Drug Substitution; D065427:Factor Xa Inhibitors; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D010644:Phenprocoumon / Q000627:therapeutic use; D000069552:Rivaroxaban; D055502:Secondary Prevention; D020521:Stroke / Q000517:prevention & control; D013876:Thiophenes / Q000627:therapeutic use*; D013923:Thromboembolism / Q000188:drug therapy*; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D009025:Morpholines; D013876:Thiophenes; D014859:Warfarin; D000069552:Rivaroxaban; D010644:Phenprocoumon